Study Summary
This trial will test a new drug, TAS1440, for safety and effectiveness in people with leukemia who have already tried other treatments that didn't work. The trial will last about 30 months.
- Acute Myeloid Leukemia
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
1 Primary · 7 Secondary · Reporting Duration: Approximately 30 months
Trial Safety
Phase-Based Safety
Awards & Highlights
Trial Design
2 Treatment Groups
TAS1440
1 of 2
TAS1440 + ATRA
1 of 2
Experimental Treatment
80 Total Participants · 2 Treatment Groups
Primary Treatment: TAS1440 · No Placebo Group · Phase 1
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 1 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Has the Food and Drug Administration given its blessing to TAS1440?
"As this is a Phase 1 investigation, which implies limited evidence of safety and efficacy, the power team has given TAS1440 a score of 1 on the scale." - Anonymous Online Contributor
Has any prior research been conducted utilizing TAS1440?
"In 2006, Memorial Sloan Kettering Cancer Center was the first to initiate research into TAS1440. Since then, 90 trials have been completed with 21 ongoing studies being conducted out of Tucson, Arizona." - Anonymous Online Contributor
How many participants are being admitted to this clinical experiment?
"To ensure the success of this research, 80 volunteers who meet the required eligibility criteria are needed. Participants may enroll through University of Arizona Cancer Center Site#127 in Tucson or Fox Chase Cancer Center Site#112 in Philadelphia." - Anonymous Online Contributor
Could you provide a tally of the venues where this trial is supervised?
"For this trial, the University of Arizona Cancer Center Site#127 in Tucson, Arizona, Fox Chase Cancer Center Site#112 in Philadelphia and the University of Michigan Medical School in Seattle are amongst the 18 sites now enrolling." - Anonymous Online Contributor
For what purposes is TAS1440 typically employed?
"TAS1440 is a recommended treatment for severe, intractable cystic acne and related issues like dermal disorders, facial skin roughness, and sun protection regimens." - Anonymous Online Contributor
Does this research endeavor have any vacancies for participants?
"Affirmative, according to records hosted on clinicaltrials.gov this study is actively recruiting participants - it was first posted on March 15th 2020 and the most recent update occurred November 18th 2022. A total of 80 patients need to be enrolled from 17 different sites." - Anonymous Online Contributor